Sulfonamides are drugs extensively used in the management of AIDS patients. However, the use of sulfonamides is often associated with the development of allergic reactions, provoking the substitution of the drug (by another that may be less effective); alternatively attempts are made to desensitize the patient. OBJECTIVE: Compare two drug regimens (full vs. escalating doses) for the oral desensitization of AIDS patients allergic to sulfonamides. MATERIAL AND METHODS: AIDS patients with previous allergic reactions to sulfonamides and requiring prophylaxis against Pneumocistis carinii, central nervous system toxoplasmosis and diarrhea caused by Isospora belli were randomly assigned to a group receiving a routine dose of cothrimoxazole, or another that received escalating doses of an oral suspension of the same drug, initiating with 75mg/day of sulfamethoxazole that was doubled every 48 hours till the full dose was reached, if no allergic reaction occurred. Patients were monitored for at least 6 months after enrollment in the trial. The major end-point was the ability to maintain prophylactic treatment after that period of time. Plasma viral load (PVL) and CD4/CD8 counts were measured at baseline. Liver enzymes and hematological parameters were measured at baseline and after 1, 3 and 6 months. RESULTS: Eighteen patients were enrolled in the study (15 men and 3 women), with ages ranging from 30 to 57 years (mean 39.9). The mean CD4 counts were slightly higher for patients receiving a full dose; there was also a trend towards higher baseline CD8 counts among patients developing new reactions. The mean PVL was similar among the patients in both desensitization groups. The incidence of new allergic reactions was identical (40%) in the two groups. All adverse reactions were mild and no significant increase in liver enzymes were observed. CONCLUSON: Dose regimen is not a predictor of the development of new allergic reactions amongst patients challenged with sulfonamides after an initial allergic reaction.

A ocorrência de casos de febre amarela (FA) e a ampla distribuição do A. aegypti no Brasil, motivou o estudo da estimativa da proteção imune contra o vírus amarílico vacinal (17D) em moradores de duas cidades do Estado da Bahia, Ipupiara (n = 461) e Prado (n = 228). Nesta área não-endêmica de FA, a pesquisa de anticorpos séricos contra o 17D (Ac17D) e contra 18 outros arbovírus, foi realizada pelo método da inibição da hemaglutinação (IH). Somente 1,2% (8/689) dos indivíduos apresentaram Ac17D, sendo seis com resposta monotípica. A resposta sorológica do tipo heterotípica para Flavivírus (FLV) foi interpretada também como associada à resposta imune ao 17D, sendo mais freqüente em Prado (30,3%) do que em Ipupiara (23,2%). A idade > ou = 50 anos e moradia em outros Estados foram associadas com a soropositividade para FLV, do mesmo modo que a história de vacinação (17D). Mas, a história de vacinação apresentou baixos percentuais de sensibilidade (£ 45,4%) e de valor preditivo-positivo (<= 38,4%), sendo altos os valores da especificidade ( > ou = 70,8%) e do valor preditivo-negativo ( > ou = 78,8%). Em conclusão, foi baixa a freqüência (1,2%) de moradores com Ac17D, apesar da freqüência maior (25,5%) de portadores de anticorpos FLV, o que significa que 26,7% da população estudada pode apresentar proteção contra o vírus da FA.

The occurrence of cases of yellow fever (YF) and also the extensive distribution of A. aegypti in Brazil, inspired a study about the estimate of immunity against vacinal virus (17D) among the residents at two cities of the Bahia state, Ipupiara (n = 461) and Prado (n = 228). At this non-endemic area of YF, the search for serology antibody against 17D (Ab17D) and 18 another arbovirus was made thereby hemagglutination inhibition (HI). Only 1.2% (8/689) showed Ab17D, six of those with monotypic sort. The heterotypic sort for flavivirus (FLV) was interpretted as associated to immunity against 17D too, being much frequent in Prado (30.3%) than in Ipupiara (23.2%). The age > or = 50 years and residence in another states were related to seropositive for FLV, the same way that vaccination's history (17D). Howener, the history of vaccination presented low percentages of sensibility (<= 45.4%) and predictive-positive value (£38.4%), but high specificity ( > or = 70.8%) and predictive-negative value ( > or = 78.8%). Therefore, the frequency of residents with Ab17D was low (1.2%), althoug the higher frequency (25.5%) of antibody FLV carrier's , what signifies that 26.7% of the studied population should present protection against the YF virus.

A cidade do Salvador, capital do Estado da Bahia, apresenta a população com maior prevalência da infecção pelo HTLV-I no Brasil. Todavia, somente um estudo incluiu uma cidade do interior deste Estado, mesmo assim com número amostral pequeno. O objetivo foi o de avaliar a prevalência de anticorpos anti-HTLV-I/II na população de quatro cidades do interior do Estado da Bahia. As amostras de soro proveninentes de 1.539 indivíduos residentes em Catolândia, Ipupiara, Jacobina e Prado foram triadas através do ELISA, e a confirmação dos resultados nas amostras repetidamente positivas foi realizada através do "Western blot". Quarenta e sete (3,1%) amostras foram positivas pelo ELISA, e 44 destas foram submetidas ao Western blot, com 5 resultados positivos (0,3%), 8 (0,5%) indeterminados (todos da cidade de Jacobina) e 31 negativos. A prevalência geral de anticorpos anti-HTLV-I, nas cidades estudadas, foi de 0,3%. Esta prevalência variou de 0,0% (Prado) a 0,7% (Jacobina), porém não houve diferença estatisticamente significante (p > 0,21). Nenhum indivíduo apresentou anticorpos anti-HTLV-II. Em conclusão, a prevalência da infecção pelo HTLV-I no interior do Estado da Bahia foi baixa, contudo, a população da cidade de Jacobina apresentou a maior prevalência. No entanto, outros estudos epidemiológicos, clínicos e virológicos serão necessários para a melhor compreensão da história natural desta infecção em Jacobina.

The city of Salvador, capital of Bahia, presents a population with the highest prevalence of HTLV-I infection in Brazil. Untill now, only one study has investigated this infection in other cities of this state, even though by using a small sample. With objective to evaluate the prevalence of HTLV-I/II antibodies in four cities of the state of Bahia. Serum samples from 1,539 individuals who lived in Catolândia, Ipupiara, Jacobina and Prado were screened by ELISA, and repeatedly reactive samples confirmed by Western Blot. Forty-seven (3.1%) samples were positive by ELISA, and 44 of them were tested by Western blot: 5 (0.3%) were positive, 8 (0.5%) were indeterminate (all of them from Jacobina) and 31 were negative. The overall prevalence of HTLV-I antibodies was 0.3%. This prevalence varied from 0.0% (Prado) to 0.7% (Jacobina), but differences were not statistically sgnificant (p > 0.21). None of these individuals presented HTLV-II antibodies. Jacobina showed the highest prevalence of HTLV-I infection among the cities studied, although the overall prevalence was low. In conclusion, further epidemiological, clinical and virological studies will be of paramount importance to obtain a better understanding of the natural history of this infection in Jacobina.